TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Disability on the Dizziness Handicap Inventory
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dizziness and related physical symptoms on the Dizziness Symptoms Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance and safety behaviors as measured by the Safety Behaviours Inventory
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in peak nevirapine concentration in plasma (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nevirapine area under the curve (AUC) from 0 to 8 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of false-negative results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of tube location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total protamine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ratio of total protamine to initial dose of heparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amount of chest tube bleeding after 12 postoperative hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in LA volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in PAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CPM-evoked PPTol increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to cold water-evoked VAS peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean ulcer size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic informativeness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impact on treatment options
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emotional burden of ICU family-team communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early withdrawal of life support
Endpoint domain: Mortality/survival
Primary endpoint: Patient preference for incision type
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Isovolumic relaxation time (IVRTcHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular relaxation time (τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular operating stiffness (LVOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: anxiety changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight-for-age Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: height-for-age Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total FTM scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chills reported
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean concentrations of IgG1 and IgG2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of pulse oximetry for detecting OSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of pulse oximetry for detecting OSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in median CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sums of the amplitudes of the QRS complexes from leads I and II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postoperative improvement in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: resting mean heart rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: relief for osteoarthritic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Oxidative burst activity in neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SSE
Endpoint domain: Mortality/survival
Primary endpoint: Spine BMD improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Hip BMD improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Tibia strength‐strain index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: mean QALYs per patient
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate-pressure product reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: combined outcome of death or major morbidity at 36 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac function parameters (CI and CFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient participation in rehabilitation activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MACE incidence at 1 year
Endpoint domain: Adverse events/effects
Primary endpoint: 20% improvement according to ACR criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in outcomes from exercise interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of AF events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of hospitalization for heart failure worsening
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Higher rate of CRTd responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease reflux index below 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: airway plus tube resistance (Rmax.aw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: airways resistance (Rmax.tr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wolf Motor Function Test Functional Ability Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Action Research Arm Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exertional fatigue (visual analogue scale)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Biomarkers of exposure to tobacco smoke toxicants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean zolpidem plasma concentrations at 15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCs from zero to 15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of zolpidem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio of femoral neck EI to TSM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Manic scores on the YMRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manic scores on daily diaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressive responses on the Point Subtraction Aggression Paradigm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative SUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection of metabolites in body fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total CC area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scintigraphic reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical events (cardiac death, MIs, admissions for unstable angina, coronary bypass grafting, angioplasty)
Endpoint domain: Mortality/survival
Primary endpoint: TEOAE amplitude alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment efficacy for TE in AIDS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cIMT decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Conversion from inadequate to adequate enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily urinary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: hearing loss
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy in facilitating accurate diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of glucagon response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Magnitude of epinephrine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in arm muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in leg muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: incidence of overall complications
Endpoint domain: Adverse events/effects
Primary endpoint: total protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: motor function of the lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aesthetic appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vein prominence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depth of metacarpal space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial complex II‐linked respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial respiratory capacity for complex I+II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modality related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cosmetic score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recognition of fearful facial expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in ADHD‐RS‐IV Inattention scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in ADHD‐RS‐IV Hyperactivity-Impulsivity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in SNAP‐IV scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: episodes of unprotected sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: peak expiratory flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effectiveness of individualized homeopathy compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged pleural effusion
Endpoint domain: Adverse events/effects
Primary endpoint: P2Y(12) reactivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Admission alive to the hospital
Endpoint domain: Mortality/survival
Primary endpoint: positive relations with others
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: sense of personal growth
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Likelihood of inpatient psychiatric admission
Endpoint domain: Adverse events/effects
Primary endpoint: VAS pain level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement (SF-12 score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knee extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Degree of insight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak subjective response to d-amph
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of itraconazole in treating pityriasis versicolor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the requirement for mastectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean reduction in MBL volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent decrease in MBL volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhinoconjunctivitis symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nighttime nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-related symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CysLTs level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imbalance of Th1 and Th2 cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anastomotic failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: requirement for surgical reintervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: absolute increase in LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BMI SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvements in cardiovascular fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Central drusen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: rates of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall infection rate after flexible cystoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: recent sexual activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual activity index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood sugar level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-extubation pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: plasma lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived pain scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in warfarin-interacting medication prescription rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: day of first and all vesicles drying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: last day of moderate‐intense pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: last day of analgesic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rescue ketamine infusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visceral adipose tissue mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: size of very large fat cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum plasma concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Peak Expiratory Flow Rate (PEFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decrease in dental anxiety scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioural avoidance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: no longer had dental phobia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adjacent-level vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of unconjugated genistein in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to synthetic epitope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Discrimination of high-grade prostate cancer at biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inconsistency in preclinical tooth preparation evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal mortality ratios
Endpoint domain: Mortality/survival
Primary endpoint: Paraspinal cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in anxiety condition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum heart rate after stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Distant metastasis rates (DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of splenomegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h DBP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced risk of developing CDMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Longer median time to CDMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lower annualised relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percent recovery on the SIS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: binocular combined visual acuities of 20/25 distance and 20/32 near
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spectacle independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic performance of perfusion-CMR vs. SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol (CHOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MHQOL outcomes at 24 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perceptual motor speed and accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-exercise cTnT elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in PASDAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in DAPSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in CPDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean peak insulin (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean insulin exposure (AUC(0‐240))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of AIx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glass‐bead retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: febrile UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: new or progressive renal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mPAP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FKN levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes